No Data
Luoxin Pharmaceutical: Report for the third quarter of 2024
luoxin pharmaceuticals group stock (002793.SZ) achieved revenue of 1.881 billion yuan in the first three quarters, a year-on-year increase of 2.98%.
Gelonghui October 29th | luoxin pharmaceuticals group stock (002793.SZ) released the third quarter report of 2024, the company achieved revenue of 1.881 billion yuan in the first three quarters, a year-on-year increase of 2.98%; with a net loss of 0.265 billion yuan. Among them, the third quarter achieved revenue of 0.622 billion yuan, a year-on-year increase of 8.87%; with a net loss of 0.177 billion yuan.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Tegora tablets obtain new indications for drug registration certificate.
luoxin pharmaceuticals group stock (002793.SZ) announced recently that its subsidiary Shandong luoxin pharmaceuticals group stock has...
Express News | Luoxin Pharmaceuticals Group Stock: Tegretol tablets new indications obtained pharmaceutical registration certificate.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Yan Jinxia will hold 0.102 billion shares and become a shareholder with more than 5% ownership.
Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that the company, together with shareholders holding more than 5% of the shares, Chengdu Dexin Huahua Private Equity Investment...
Express News | Luoxin Pharmaceuticals Group Stock: Shareholders intend to transfer 0.102 billion shares of the company by agreement.
No Data
No Data